The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Dysfunctional HDL and atherosclerotic cardiovascular disease
Open accessAbstract
High-density lipoproteins (HDLs) protect against atherosclerosis by removing excess cholesterol from macrophages through the ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) pathways involved in reverse cholesterol transport. Factors that impair the availability of functional apolipoproteins or the activities of ABCA1 and ABCG1 could, therefore, strongly influence atherogenesis. HDL also inhibits lipid oxidation, restores endothelial function, exerts anti-inflammatory and antiapoptotic actions, and exerts anti-inflammatory actions in animal models. Such properties could contribute considerably to the capacity of HDL to inhibit atherosclerosis. Systemic and vascular inflammation has been proposed to convert HDL to a dysfunctional form that has impaired antiatherogenic effects. A loss of anti-inflammatory and antioxidative proteins, perhaps in combination with a gain of proinflammatory proteins, might be another important component in rendering HDL dysfunctional. The proinflammatory enzyme myeloperoxidase induces both oxidative modification and nitrosylation of specific residues on plasma and arterial apolipoprotein A-I to render HDL dysfunctional, which results in impaired ABCA1 macrophage transport, the activation of inflammatory pathways, and an increased risk of coronary artery disease. Understanding the features of dysfunctional HDL or apolipoprotein A-I in clinical practice might lead to new diagnostic and therapeutic approaches to atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Some studies have indicated a complete loss of function and dysfunction gain concerning anti-inflammatory, vasodilatory, and antiapoptotic activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, there are instances where HDL’s ability to deliver cholesterol esters via SCARB1 may be reduced, indicating only a partial loss of function.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“It was noted that HDL could lose its anti-inflammatory properties and even develop proinflammatory characteristics.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“However, when it comes to antioxidative activity and cholesterol efflux capacity, the deficiency observed in HDL’s normal function falls short of complete dysfunction [9].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Subsequent research has shown that the extent of HDL’s normal function loss and dysfunction gain can vary depending on its different biological activities.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Dysfunctional HDL (dys-HDL) are HDL cholesterol particles with high pro-atherogenic characteristics, characterized by the loss of typical antioxidant properties, becoming carriers of oxidized lipids themselves.”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [9]
In the citing paper
“Moreover, modulations in HDL particle composition can transform it to dysfunctional and, through this modulation, increase the risk of CVD40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
In the citing paper
“Decrease in HDL has been regarded as one important risk factor for cardiovascular diseases40.”
From Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses (2016) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Self-citationEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationCholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Large-scale association analysis identifies new risk loci for coronary artery disease
The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2480 · Cited by 1,614
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390
Daugherty, A., Dunn, J. L., Rateri, D. L., & Heinecke, J. W. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117342 · Cited by 1,269
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 821
Apolipoprotein A-II, a Player in Multiple Processes and Diseases
Florea, G., Tudorache, I. F., Fuior, E. V., Ioniță, R., Dumitrescu, M., Fenyo, I. M., Trusca, V. G., & Gafencu, A. V. (2022) · Biomedicines · doi:10.3390/biomedicines10071578 · Cited by 55
Dysfunctional High-Density Lipoprotein Cholesterol and Coronary Artery Disease: A Narrative Review
Madaudo, C., Bono, G., Ortello, A., Astuti, G., Mingoia, G., Galassi, A. R., & Sucato, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14090996 · Cited by 57
The HDL cholesterol/apolipoprotein A-I ratio: an indicator of cardiovascular disease
Rhee, E., Byrne, C. D., & Sung, K. (2017) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000315 · Cited by 52
Sarin, H. V., Lee, J. H., Jauhiainen, M., Joensuu, A., Borodulin, K., Männistö, S., Jin, Z., Terwilliger, J. D., Isola, V., Ahtiainen, J. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40107-6 · Cited by 52
Ungurianu, A., Margina, D. M., Grădinaru, D., Băcanu, C., Ilie, M., Tsitsimpikou, C., Tsarouhas, K., Spandidos, D. A., & Tsatsakis, A. M. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5972 · Cited by 51
Update on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Kazzi, M. E., Rayner, B. S., Chami, B., Dennis, J. M., Thomas, S. R., & Witting, P. K. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7928 · Cited by 53
Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 58
High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management
Choi, H. Y., Hafiane, A., Schwertani, A. G., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.09.012 · Cited by 51
Zhu, R., Sun, Y., Hou, Y., Fan, J., Chen, G., & Li, T. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.05.018 · Cited by 51
High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk
Asztalos, B. F., Horvath, K. V., & Schaefer, E. J. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311117 · Cited by 50
Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease
Estrada-Luna, D., Ortiz-Rodríguez, M. A., Medina-Briseño, L., Carreón‐Torres, E., Vega, J. A. I., Sharma, A. K., Cancino‐Díaz, J. C., Pérez-Méndez, O. A., Belefant‐Miller, H., & Cabrera, G. B. (2018) · Molecules · doi:10.3390/molecules23112730 · Cited by 51
HDL flux is higher in patients with nonalcoholic fatty liver disease
McCullough, A. J., Previs, S. F., Dasarathy, J., Lee, K., Ösme, A., Kim, C., Ilchenko, S., Lorkowski, S. W., Smith, J. D., Dasarathy, S., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2019 · Cited by 53
Zimetti, F., Adorni, M. P., Marsillach, J., Marchi, C., Trentini, A., Valacchi, G., & Cervellati, C. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6695796 · Cited by 49
Advances in high-density lipoprotein physiology: surprises, overturns, and promises
Constantinou, C., Karavia, E. A., Xepapadaki, E., Πετροπούλου, Π.-Ι., Παπακώστα, Ε., Karavyraki, M., Zvintzou, E., Theodoropoulos, V., Filou, S., Hatziri, A., et al. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00429.2015 · Cited by 48
Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19
Aparisi, Á., Iglesias-Echeverría, C., Ybarra-Falcón, C., Cusácovich, I., Uribarri, A., García-Gómez, M., Ladrón, R., Fuertes, R., Candela, J., Tobar, J., et al. (2021) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.016 · Cited by 48
Santos, H. O., & Lavie, C. J. (2021) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.01.033 · Cited by 48
Wengrofsky, P., Lee, J., & Makaryus, A. N. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85772 · Cited by 54
Harbaum, L., Ghataorhe, P., Wharton, J., Jiménez, B., Howard, L., Gibbs, J. S. R., Nicholson, J. K., Rhodes, C. J., & Wilkins, M. R. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-212144 · Cited by 44
Bardagjy, A. S., & Steinberg, F. M. (2019) · Nutrients · doi:10.3390/nu11061231 · Cited by 48
Leng, J., Zhang, J., Li, C., Shu, C., Wang, B., Lin, R., Liang, Y., Wang, K., Shen, L., Lam, K. H., et al. (2021) · Biomedical Optics Express · doi:10.1364/boe.420724 · Cited by 47
The High-Density Lipoprotein Puzzle
Rosenson, R. S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 44
Self-citationZhang, L., Yermalitsky, V. N., Huang, J., Pleasent, T., Borja, M. S., Oda, M. N., Jerome, W. G., Yancey, P. G., Linton, M. F., & Davies, S. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001099 · Cited by 43
Qin, X., Li, J., Wu, T., Wu, Y., Tang, X., Gao, P., Li, L., Wang, M., Wu, Y. Y., Wang, X., et al. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0784-0 · Cited by 45
Prats‐Uribe, A., Sayols-Baixeras, S., Fernández‐Sanlés, A., Subirana, I., Carreras‐Torres, R., Vilahur, G., Civeira, F., Marrugat, J., Fitó, M., Hernáez, Á., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154351 · Cited by 45
Lu, J., Han, G., Liu, X., Chen, B., Peng, K., Shi, Y., Zhang, M., Yang, Y., Cui, J., Song, L., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100874 · Cited by 42
MiR-486 regulates cholesterol efflux by targeting HAT1
Liu, D., Zhang, M., Xie, W., Lan, G., Cheng, H., Gong, D., Huang, C., Lv, Y.-C., Yao, F., Tan, Y. L., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.11.128 · Cited by 41
Beneficial Effects Exerted by Paeonol in the Management of Atherosclerosis
Lü, L., Qin, Y., Chen, C., & Guo, X. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/1098617 · Cited by 42
ABCA1-Derived Nascent High-Density Lipoprotein–Apolipoprotein AI and Lipids Metabolically Segregate
Xu, B., Gillard, B. K., Gotto, A. M., Rosales, C., & Pownall, H. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310290 · Cited by 41
Guo, K., Hu, L., Xi, D., Zhao, J., Liu, J., Luo, T., Ma, Y., Lai, W., & Guo, Z. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.013 · Cited by 40
Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., & Sanoudou, D. (2018) · Journal of Personalized Medicine · doi:10.3390/jpm8040034 · Cited by 41
Lipoprotein(a): Current Evidence for a Physiologic Role and the Effects of Nutraceutical Strategies
Santos, H. O., KONES, R. J., Rumana, U., Earnest, C. P., Izidoro, L. F. M., & Macedo, R. C. O. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.06.002 · Cited by 42
Freeman, L. A., Demosky, S. J., Konaklieva, M. I., Kuskovsky, R., Aponte, A. M., Ossoli, A., Gordon, S. M., Koby, R. F., Manthei, K. A., Shen, M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240457 · Cited by 41
Fu, Z., Liu, Q., Liang, J., Weng, Z., Li, W., Xu, J., Zhang, X., Xu, C., & Gu, A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac252 · Cited by 42
Structural Insights into High Density Lipoprotein: Old Models and New Facts
Gogonea, V. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00318 · Cited by 41
Liu, Q., Zhang, H., Lin, J., Zhang, R., Chen, S., Liu, W., Sun, M., Du, W., Hou, J., & Yu, B. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13196 · Cited by 39
High-Density Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune Response
Taborda, N. A., Blanquiceth, Y., Inchima, S. U., Latz, E., & Hernández, J. C. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2019.0029 · Cited by 40
Christakoudi, S., Ríboli, E., Εvangelou, Ε., & Tsilidis, K. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-12284-4 · Cited by 40
Dysfunctional high-density lipoprotein: an updated review
Ouyang, F. W., Chiang, H., Hsu, W., Tsai, M.-H., Huang, C.-Y., Remaley, A. T., Akyol, Ö., & Chen, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1713387 · Cited by 40
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 39
van Capelleveen, J. C., Kastelein, J. J. P., Zwinderman, A. H., van Deventer, S. J. H., Collins, H. L., Adelman, S. J., Round, P., Ford, J., Rader, D. J., & Hovingh, G. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.006 · Cited by 42
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 42
Li, H.-M., Mo, Z.-W., Peng, Y.-M., Li, Y., Dai, W.-P., Yuan, H., Chang, F.-J., Wang, T., Wang, M., Hu, K.-H., et al. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101642 · Cited by 39
Domingo‐Espín, J., Lindahl, M., Nilsson, O., Cushman, S. W., Stenkula, K. G., & Lagerstedt, J. O. (2016) · Diabetes · doi:10.2337/db15-1493 · Cited by 38
Asleh, R., Levy, A. P., Levy, N. S., Asleh, A., Goldenstein, H., Segol, I., Gulati, R., Lerman, L. O., & Lerman, A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312232 · Cited by 38
Structure-based mechanism and inhibition of cholesteryl ester transfer protein
Han, X. M., Zhang, M., Liu, J., Wang, J., & Ren, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01087-1 · Cited by 37
Jiménez‐Osorio, A. S., Carreón‐Torres, E., Solís, E. C., Angel-García, J., Arias‐Rico, J., Jiménez-Garza, O., Castillejos, L. M., Díaz-Zuleta, H. A., Téllez, R. M. B., Sánchez-Padilla, M. L., et al. (2023) · Antioxidants · doi:10.3390/antiox12101894 · Cited by 46
Cao, L., Zhang, J., Yu, L., Yang, W. Q., Qi, W., Ren, R., Liu, Y., Hou, Y., Cao, Y., Li, Q., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186509 · Cited by 38
Orsoni, A., Thérond, P., Tan, R., Giral, P., Robillard, P., Kontush, A., Meikle, P. J., & Chapman, M. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p068585 · Cited by 37
Self-citationHigh-Density Lipoprotein Cholesterol in Age-Related Ocular Diseases
Betzler, B. K., Rim, T. H., Sabanayagam, C., Cheung, C. M. G., & Cheng, C. (2020) · Biomolecules · doi:10.3390/biom10040645 · Cited by 37
Song, W., Wang, W., Dou, L.-Y., Wang, Y., Xu, Y., Chen, L., & Yan, X. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p055491 · Cited by 36
Porphyromonas gingivalisaccelerates atherosclerosis through oxidation of high-density lipoprotein
Kim, H., Cha, G. S., Kim, H. J., Kwon, E.-Y., Lee, J. Y., Choi, J., & Joo, J. (2018) · Journal of Periodontal & Implant Science · doi:10.5051/jpis.2018.48.1.60 · Cited by 36
Sigal, G. A., Tavoni, T. M., Silva, B. M. O., Filho, R. K., Brandão, L. G., & Maranhão, R. C. (2018) · Thyroid · doi:10.1089/thy.2018.0190 · Cited by 36
Azemi, N. A., Azemi, A. K., Abu-Bakar, L., Vigneswari, S., Muhammad, T. S. T., & Ismail, N. (2022) · Metabolites · doi:10.3390/metabo13010053 · Cited by 42
Interplay between cigarette smoking and pulmonary reverse lipid transport
Jubinville, É., Talbot, M., Bérubé, J., Hamel-Auger, M., Maranda-Robitaille, M., Beaulieu, M., Aubin, S., Paré, M., Kallend, D. G., Arsenault, B. J., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00681-2017 · Cited by 36
López, P., Rodríguez‐Carrio, J., Martínez-Zapico, A., Pérez-Álvarez, Á. I., López‐Mejías, R., Benavente, L., Mozo, L., Caminal‐Montero, L., González-Gay, M. Á., & Suárez, A. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0221 · Cited by 36
Liu, D., Liang, J., Zhao, M., Wang, Y., Guo, Y., Li, L., Zhang, D., Xu, L., Pan, B., Su, J., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.08.001 · Cited by 35
Zheng, J. J., Agus, J., Hong, B. V., Tang, X., Rhodes, C. H., Houts, H. E., Zhu, C., Kang, J. W., Wong, M., Xie, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95451-3 · Cited by 39
Zhang, A. L., Balmes, J. R., Lutzker, L., Mann, J. K., Margolis, H. G., Tyner, T. R., Holland, N., Noth, E. M., Lurmann, F. W., Hammond, S. K., et al. (2021) · Journal of Exposure Science & Environmental Epidemiology · doi:10.1038/s41370-021-00378-6 · Cited by 37
Theofilatos, D., Fotakis, P., Valanti, E., Sanoudou, D., Zannis, V. I., & Kardassis, D. (2018) · Metabolism · doi:10.1016/j.metabol.2018.06.002 · Cited by 34
Genomic Variants and Multilevel Regulation of ABCA1, ABCG1, and SCARB1 Expression in Atherogenesis
Rozhkova, A. V., Dmitrieva, V. G., Nosova, E. V., Dergunov, A. D., Limborska, S. A., & Dergunova, L. V. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8120170 · Cited by 39
von Eckardstein, A., & Rohrer, L. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000294 · Cited by 33
TCM Regulates PI3K/Akt Signal Pathway to Intervene Atherosclerotic Cardiovascular Disease
Liu, J., Xu, P., Liu, D., Wang, R., Cui, S., Zhang, Q., Li, Y., Yang, W., & Zhang, D. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/4854755 · Cited by 33
Sun, A., Yang, H., Li, T., Luo, J., Zhou, L., Chen, R., Han, L., & Lin, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1368950 · Cited by 38
Chuang, S., Liu, S.-C., Chien, M.-N., Lee, C., Lee, Y., & Chien, K. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100869 · Cited by 35
Romani, A., Trentini, A., van der Flier, W. M., Bellini, T., Zuliani, G., Cervellati, C., & Teunissen, C. E. (2020) · Antioxidants · doi:10.3390/antiox9050456 · Cited by 33
Hunjadi, M., Lamina, C., Kahler, P., Bernscherer, T., Viikari, J. S. A., Lehtimäki, T. J., Kähönen, M. A. P., Hurme, M., Juonala, M., Taittonen, L. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76146-7 · Cited by 35
The Effect of Hyperlipidemia on the Course of Diabetic Retinopathy—Literature Review
Bryl, A., Mrugacz, M., Falkowski, M., & Zorena, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102761 · Cited by 33
Sexual Dimorphism in Lipid Metabolism and Gut Microbiota in Mice Fed a High-Fat Diet
Zhu, Q., Qi, N., Shen, L., Lo, C. C., Xu, M., Duan, Q., Ollberding, N. J., Wu, Z. B., Hui, D. Y., Tso, P., et al. (2023) · Nutrients · doi:10.3390/nu15092175 · Cited by 32
Functional Lipids and Cardiovascular Disease Reduction: A Concise Review
Omachi, D. O., Aryee, A. N. A., & Onuh, J. O. (2024) · Nutrients · doi:10.3390/nu16152453 · Cited by 36
Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters
Dong, B., Young, M. A., Liu, X., Singh, A. B., & Liu, J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m070888 · Cited by 33
Endotoxemia is associated with an adverse metabolic profile
Määttä, A.-M., Salminen, A., Pietiäinen, M., Leskelä, J., Palviainen, T., Sattler, W., Sinisalo, J. P., Salomaa, V. V., Kaprio, J. A., & Pussinen, P. J. (2020) · Innate Immunity · doi:10.1177/1753425920971702 · Cited by 32
Sanllorente, A., Soria-Florido, M. T., Castañer, O., Lassale, C. M., Salas‐Salvadó, J., Martínez‐González, M. Á., Subirana, I., Ros, E., Corella, D., Estruch, R., et al. (2021) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqab246 · Cited by 32
Sergi, D., Zauli, E., Tisato, V., Secchiero, P., Zauli, G., & Cervellati, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054403 · Cited by 32
Tardif, J., Rhainds, D., Rhéaume, É., & Dubé, M. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307122 · Cited by 32
Guo, J., Chen, M., Yu, H. H., Huang, Y., Zhang, H., Yuan, Z., Zhou, B., & Fu, M. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s425663 · Cited by 32
Modified lipoproteins in periodontitis: a link to cardiovascular disease?
Ljunggren, S., Bengtsson, T., Karlsson, H., Johansson, C. S., Palm, E. C., Nayeri, F., Ghafouri, B., Davies, J. R., Svensäter, G., & Lönn, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181665 · Cited by 32
Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis
Getz, G. S., & Reardon, C. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00536 · Cited by 36
Lee, S., Lee, M.-S., Chang, E., Lee, Y., Lee, J., Kim, J., Kim, C., Kim, I.-H., & Kim, Y. (2020) · Nutrients · doi:10.3390/nu12051499 · Cited by 33
Huang, R., Yan, L., & Lei, Y. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00863-x · Cited by 31
Modulatory effect of garcinol in streptozotocin-induced diabetic Wistar rats
Madhuri, K., & Naik, P. R. (2017) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2017.1336632 · Cited by 31
HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic
Morin, E. E., Li, X., & Schwendeman, A. A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00715 · Cited by 31
Vekić, J., Zeljković, A., Al‐Rasadi, K., Cesur, M., Silva‐Nunes, J., Stoian, A. P., & Rizzo, M. (2022) · Metabolites · doi:10.3390/metabo12020108 · Cited by 30
Chapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 36
Self-citationAnderson, J. L. C., Gautier, T., Nijstad, N., Tölle, M., Schuchardt, M., van der Giet, M., & Tietge, U. J. F. (2017) · Scientific Reports · doi:10.1038/srep41481 · Cited by 30
Psoriasis-associated vascular disease: the role of HDL
Lopes, M. J. P., & Alves, J. D. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0382-4 · Cited by 31
Holme, S. A. N., Sigsgaard, T., Holme, J. A., & Holst, G. J. (2020) · Particle and Fibre Toxicology · doi:10.1186/s12989-020-00367-x · Cited by 30
Reproducible Determination of High-Density Lipoprotein Proteotypes
Goetze, S., Frey, K., Rohrer, L., Radosavljevic, S., Krützfeldt, J., Landmesser, U., Bueter, M., Pedrioli, P. G. A., von Eckardstein, A., & Wollscheid, B. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00429 · Cited by 29
Thambiah, S. C., & Lai, L. C. (2021) · Practical Laboratory Medicine · doi:10.1016/j.plabm.2021.e00248 · Cited by 35
Novel Anti-Inflammatory Therapies in Coronary Artery Disease and Acute Coronary Syndromes
Dimitroglou, Y., Aggeli, C., Theofilis, P., Tsioufis, P., Oikonomou, E. K., Chasikidis, C., Tsioufis, K. P., & Tousoulis, D. (2023) · Life · doi:10.3390/life13081669 · Cited by 35
Chen, Q., Zhang, Y., Ding, D., Li, D., Xia, M., Li, X., Yang, Y., Li, Q., Hu, G., & Ling, W. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.08.324 · Cited by 31
Poonia, R. C., & Al-Alshaikh, H. A. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108874 · Cited by 31
Yamashita, S., & Matsuzawa, Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000332 · Cited by 30
Zuo, S., Wang, G., Han, Q., Xiao, H., Santos, H. O., Rodriguez, D. A., Khani, V., & Tang, J. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2020.102450 · Cited by 29
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease
Mathew, R. O., Rosenson, R. S., Lyubarova, R., Chaudhry, R., Costa, S. P., Bangalore, S., & Sidhu, M. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07020-x · Cited by 29
Self-citationSu, X., Zhang, G., Cheng, Y., & Wang, B. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06553-0 · Cited by 29
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys
Noveir, S. D., Kerman, B. E., Xian, H., Meuret, C. J., Smadi, S., Martinez, A. E., Johansson, J., Zetterberg, H., Parks, B. A., Kuklenyik, Z., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01028-1 · Cited by 30
Torres, A. C. M. B. G., Leite, N., Tureck, L. V., de Souza, R. L. R., Titski, A. C. K., Milano, G. E., Lazarotto, L., da Silva, L. R., & Alle, L. F. (2018) · Gene · doi:10.1016/j.gene.2018.11.065 · Cited by 32
Cholesterol Acceptors Regulate the Lipidome of Macrophage Foam Cells
Paul, A., Lydic, T. A., Hogan, R., & Goo, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153784 · Cited by 28
Shi, J., Yang, M. M., Yang, S., Fan, F., Zhang, J., Miao, Y., Hua, Y., Zhang, J., Cheng, Y., Liu, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155489 · Cited by 30
Metadata
- Authors
- Rosenson, R. S., Brewer, H. B., Ansell, B. J., Barter, P., Chapman, M. J., Heinecke, J. W., Kontush, A., Tall, A. R., & Webb, N. R.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- MedStar Washington Hospital Center (US)
- University of California, Los Angeles (US)
- UNSW Sydney (AU)
- Inserm (FR)
- University of Washington (US)
- Columbia University (US)
- University of Kentucky (US)
- Corresponding author
- Rosenson, Robert S.
- Venue
- Nature Reviews Cardiology
- Published
- 2015-09-01
- Volume
- 13
- Issue
- 1
- Pages
- 48-60
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC6245940
- OpenAlex
- W2175680864
- Cited by
- 822
- References
- 131
- Citations by year
- 2026: 89 · 2025: 89 · 2024: 66 · 2023: 79 · 2022: 86 · 2021: 79 · 2020: 79 · 2019: 62 · 2018: 69 · 2017: 61 · 2016: 56 · 2015: 5
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK108209, P30DK017047)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- HDL dysfunction, atherosclerosis, apolipoprotein A-I, reverse cholesterol transport, ABCA1, ABCG1, myeloperoxidase, nitrosylation, oxidative modification, inflammation, endothelial function, coronary artery disease, atherogenesis, anti-inflammatory activity
- MeSH terms
- Humans, Lipoproteins, HDL, Macrophages, Smoking, Apolipoprotein A-I, ATP-Binding Cassette Transporters, Diabetes Complications, Atherosclerosis, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
